Journal for ImmunoTherapy of Cancer《癌症免疫治疗杂志》(可网站投稿)

Journal for ImmunoTherapy of Cancer《癌症免疫治疗杂志》(月刊). The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

杂志简称:j immunother cancer
中文译名:《癌症免疫治疗杂志》
收录属性:高质量科技期刊(t3), scie(2024版), 目次收录(维普),英文期刊,
自引率:4.90%
投稿方向:医学、immunology 免疫学、oncology 肿瘤学

Journal for ImmunoTherapy of Cancer《癌症免疫治疗杂志》

SCI/E期刊基本信息

出版周期:月刊 地区:英国
中科院分区:2区
是否TOP:非TOP期刊
是否综述:非综述期刊
是否OA:OA期刊
国际标准刊号:ISSN2051-1426;EISSN2051-1426
杂志语言:英语
出版国家:英国

杂志官网 联系方式

出版地址:BRITISH MED ASSOC HOUSE,TAVISTOCK SQUARE,LONDON,ENGLAND,WC1H 9JR
杂志邮箱:
投稿网址:https://mc.manuscriptcentral.com/jitc
杂志官方网址:https://jitc.biomedcentral.com/
出版商网址:http://www.bmjjournals.com

杂志投稿要求

投稿须知【杂志社官方网站信息】

Authors

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. It publishes articles under several sections: Basic Tumor Immunology, Clinical/Translational Cancer Immunotherapy, Immune Cell Therapies and Immune Cell Engineering, Immunotherapy Biomarkers, and Oncolytic and Local Immunotherapy. Additional information about these sections can be found here.

Benefits of Publishing in JITC

Open Access and No Copyright Transfer

All content published in JITC is freely available upon publication.

High Impact Factor

JITC increased its Impact Factor to 10.252 in October 2020. JITC’s Impact Factor places the journal in the top 3 percent of all fully open access oncology journals and ranks in the top 8 percent of all journals published in the categories of oncology and immunology.

Stringent Ethical Standards

JITC is published by BMJ, a member of the Committee on Publishing Ethics.

Visibility

JITC is featured in a number of major indexing resources, including PubMed, PubMed Central, MEDLINE, the Directory of Open Access Journals (DOAJ), Scopus, and Clarivate Analyics’ Science Citation Index Expanded (SCIE).

Editorial Policies

JITC adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. The journal follows guidance produced by bodies that include the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME) and the International Committee of Medical Journal Editors (ICMJE). To view all BMJ Journal policies, please refer to the BMJ Author Hub policies page.

We take seriously all possible misconduct. If an editor, author, or reader has concerns that a submitted article describes something that might be considered to constitute misconduct in research, publication or professional behavior, they should forward their concerns to the journal. The publisher will deal with allegations appropriately.

For guidelines on policies and submissions across our journals, please click on the links below:

Manuscript Preparation

Editorial Policies

Patient Consent Forms

License Forms

Peer Review

Submission and Production Processes

刊知网 精心整理,转载请注明出处:https://www.kanzhiwang.com/archives/44187

我要点评 请您把投稿经验分享出来 让大家少走弯路少踩坑,我为人人、人人为我。

内容纠错 杂志信息如有错漏 请在下方留言。

上一篇 2025年2月26日 下午3:40
下一篇 2025年2月26日 下午3:49

相关推荐

发表回复

登录后才能评论

联系我们

191 1833 1195

QQ:321628655
邮件:321628655@qq.com

工作时间:周一至周五,9:30-18:30,节假日休息